Remarkably Similar CTLA-4 Binding Properties of Therapeutic Ipilimumab and Tremelimumab Antibodies

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Oct 6

PMID 28978021

Citations 49

Authors

Mengnan He

Yan Chai

Jianxun Qi

Catherine W H Zhang

Zhou Tong

Yi Shi

Jinghua Yan

Shuguang Tan

George F Gao

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibody based immune checkpoint blockade therapies have achieved clinical successes in management of malignant tumors. As the first monoclonal antibody targeting immune checkpoint molecules entered into clinics, the molecular basis of ipilimumab-based anti-CTLA-4 blockade has not yet been fully understood. In the present study, we report the complex structure of ipilimumab and CTLA-4. The complex structure showed similar contributions from VH and VL of ipilimumab in binding to CTLA-4 front β-sheet strands. The blockade mechanism of ipilimumab is that the strands of CTLA-4 contributing to the binding to B7-1 or B7-2 were occupied by ipilimumab and thereafter prevents the binding of B7-1 or B7-2 to CTLA-4. Though ipilimumab binds to the same epitope with tremelimumab on CTLA-4 with similar binding affinity, the higher dissociation rate of ipilimumab may indicate the dynamic binding to CTLA-4, which may affect its pharmacokinetics. The molecular basis of ipilimumab-based anti-CTLA-4 blockade and comparative study of the binding characteristics of ipilimumab and tremelimumab would shed light for the discovery of small molecular inhibitors and structure-based monoclonal antibody optimization or new biologics.

Citing Articles

Design of high-affinity binders to immune modulating receptors for cancer immunotherapy.

Yang W, Hicks D, Ghosh A, Schwartze T, Conventry B, Goreshnik I Nat Commun. 2025; 16(1):2001.

PMID: 40011465 PMC: 11865580. DOI: 10.1038/s41467-025-57192-z.

Engineered ipilimumab variants that bind human and mouse CTLA-4.

Robison B, Diong S, Kumar A, Moon T, Chang O, Chau B MAbs. 2025; 17(1):2451296.

PMID: 39849917 PMC: 11776466. DOI: 10.1080/19420862.2025.2451296.

Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.

Chand D, Savitsky D, Krishnan S, Mednick G, Delepine C, Garcia-Broncano P Cancer Discov. 2024; 14(12):2407-2429.

PMID: 39083809 PMC: 11609826. DOI: 10.1158/2159-8290.CD-24-0190.

Design of High Affinity Binders to Convex Protein Target Sites.

Yang W, Hicks D, Ghosh A, Schwartze T, Conventry B, Goreshnik I bioRxiv. 2024; .

PMID: 38746206 PMC: 11092582. DOI: 10.1101/2024.05.01.592114.

Cancer therapy with antibodies.

Paul S, Konig M, Pardoll D, Bettegowda C, Papadopoulos N, Wright K Nat Rev Cancer. 2024; 24(6):399-426.

PMID: 38740967 PMC: 11180426. DOI: 10.1038/s41568-024-00690-x.

References

Gao G, Jakobsen B . Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. Immunol Today. 2000; 21(12):630-6. DOI: 10.1016/s0167-5699(00)01750-3. View

Schwartz J, Zhang X, Fedorov A, Nathenson S, Almo S . Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature. 2001; 410(6828):604-8. DOI: 10.1038/35069112. View

Stamper C, Zhang Y, Tobin J, Erbe D, Ikemizu S, Davis S . Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature. 2001; 410(6828):608-11. DOI: 10.1038/35069118. View

Read R . Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr. 2001; 57(Pt 10):1373-82. DOI: 10.1107/s0907444901012471. View

Gao G, Rao Z, Bell J . Molecular coordination of alphabeta T-cell receptors and coreceptors CD8 and CD4 in their recognition of peptide-MHC ligands. Trends Immunol. 2002; 23(8):408-13. DOI: 10.1016/s1471-4906(02)02282-2. View

Emsley P, Cowtan K . Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2126-32. DOI: 10.1107/S0907444904019158. View

Adams P, Afonine P, Bunkoczi G, Chen V, Davis I, Echols N . PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 2):213-21. PMC: 2815670. DOI: 10.1107/S0907444909052925. View

Lee C, Tannock I . The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer. 2010; 10:255. PMC: 2889896. DOI: 10.1186/1471-2407-10-255. View

Ribas A, Kefford R, Marshall M, Punt C, Haanen J, Marmol M . Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013; 31(5):616-22. PMC: 4878048. DOI: 10.1200/JCO.2012.44.6112. View

10.

Lafferty K, Cunningham A . A new analysis of allogeneic interactions. Aust J Exp Biol Med Sci. 1975; 53(1):27-42. DOI: 10.1038/icb.1975.3. View

11.

Furness A, Vargas F, Peggs K, Quezada S . Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol. 2014; 35(7):290-8. DOI: 10.1016/j.it.2014.05.002. View

12.

Maio M, Grob J, Aamdal S, Bondarenko I, Robert C, Thomas L . Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015; 33(10):1191-6. PMC: 5795709. DOI: 10.1200/JCO.2014.56.6018. View

13.

Romano E, Kusio-Kobialka M, Foukas P, Baumgaertner P, Meyer C, Ballabeni P . Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015; 112(19):6140-5. PMC: 4434760. DOI: 10.1073/pnas.1417320112. View

14.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. PMC: 5698905. DOI: 10.1056/NEJMoa1504030. View

15.

Joshua A, Monzon J, Mihalcioiu C, Hogg D, Smylie M, Cheng T . A phase 2 study of tremelimumab in patients with advanced uveal melanoma. Melanoma Res. 2015; 25(4):342-7. DOI: 10.1097/CMR.0000000000000175. View

16.

Mahoney K, Rennert P, Freeman G . Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015; 14(8):561-84. DOI: 10.1038/nrd4591. View

17.

Valsecchi M . Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(13):1270. DOI: 10.1056/NEJMc1509660. View

18.

Maute R, Gordon S, Mayer A, McCracken M, Natarajan A, Ring N . Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci U S A. 2015; 112(47):E6506-14. PMC: 4664306. DOI: 10.1073/pnas.1519623112. View

19.

Antonia S, Goldberg S, Balmanoukian A, Chaft J, Sanborn R, Gupta A . Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016; 17(3):299-308. PMC: 5500167. DOI: 10.1016/S1470-2045(15)00544-6. View

20.

Zak K, Grudnik P, Guzik K, Zieba B, Musielak B, Domling A . Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016; 7(21):30323-35. PMC: 5058683. DOI: 10.18632/oncotarget.8730. View